Hospital Consultation From Outpatient Clinicians for Medically Complex Children: A Randomized Clinical Trial

Ricardo A Mosquera1,2, Elenir B C Avritscher1,2, Claudia Pedroza1,2

  • 1Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston.

JAMA Pediatrics
|November 30, 2020
PubMed

Insights

Hospital consultation (HC) services for children with medical complexity (CMC) receiving comprehensive care (CC) likely reduced hospital days, hospitalizations, and costs. This intervention improved care continuity for high-risk pediatric patients.

Area of Science:

  • Pediatric Healthcare
  • Health Services Research
  • Complex Care Management

Background:

  • Children with medical complexity (CMC) often experience fragmented care, leading to adverse outcomes.
  • Outpatient comprehensive care (CC) has shown promise in reducing serious illnesses and hospitalizations for high-risk CMC.
  • Continuity of care remains a challenge, frequently disrupted by emergency department (ED) visits and hospitalizations.

Purpose of the Study:

  • To evaluate the effectiveness of a hospital consultation (HC) service for CMC, delivered by their outpatient CC clinicians.
  • To assess the impact of HC on hospital utilization and costs for high-risk CMC.

Main Methods:

  • A randomized quality improvement trial was conducted at a tertiary pediatric hospital.
  • Participants included high-risk CMC receiving CC, randomized to either HC or usual hospital care (UHC).
  • Data on total hospital days, PICU days, hospitalizations, and health system costs were analyzed using Bayesian methods.

Main Results:

  • The HC group showed a high probability of reduced total hospital days (91%) and hospitalizations (98%) compared to UHC.
  • Probabilities for reduced PICU days (89%) and health system costs (94%) were also significant.
  • Bayesian analysis, incorporating expert opinion, further supported the benefits of HC.

Conclusions:

  • A hospital consultation (HC) service integrated with outpatient comprehensive care (CC) likely improves outcomes for children with medical complexity (CMC).
  • This intervention demonstrated potential to reduce hospital days, hospitalizations, PICU utilization, and associated health system costs.
  • Further trials are recommended to validate HC services for CMC in diverse settings.
Abstract

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
117
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
64
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
141
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
93